Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (261)
Cancellation by sponsor (83)
Prescription medicine registration (27)
Section 14, TGO91 consent (6)
Australian public assessment report (AusPar) (1)
Prescription medicine decision summary (1)

Date

2026 (2)
2025 (23)
2024 (13)
2023 (18)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (17)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

379 result(s) found, displaying 271 to 280

Latanoprost/Timolol AMNEAL 50/5 latanoprost 50 microgram/mL + timolol (as maleate) 5 mg/mL eye drop solution bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
Latanoprost/Timolol KP 50/5 latanoprost 50 microgram/mL + timolol (as maleate) 5 mg/mL eye drop solution bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
VALGANCICLOVIR AN valganciclovir (as hydrochloride) 450 mg film coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
VALGANCICLOVIR CH valganciclovir (as hydrochloride) 450 mg film coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
VALGANCICLOVIR AMNEAL valganciclovir (as hydrochloride) 450 mg film coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
VALGANCICLOVIR KP valganciclovir (as hydrochloride) 450 mg film coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
LANTIM 50/5 latanoprost 50 microgram/mL and timolol 5 mg/mL (as maleate) eye drops solution bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
GLIVANIB imatinib (as mesilate) 100 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
GLIVANIB imatinib (as mesilate) 400 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
LEZOLE letrozole 2.5 mg film-coated tablets blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 24
Page 25
Page 26
Page 27
Current page 28
Page 29
Page 30
Page 31
Page 32
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.